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Diffuse gliomas are primary brain tumors characterized by infiltrative growth 
and high heterogeneity, rendering the disease mostly incurable. Advances in genetic 
analysis have characterized molecular alterations affecting patients’ overall survival 
and clinical outcome, particularly in glioblastoma (GBM). However, glioma 
tumorigenicity is not exclusively controlled by its genetic alterations. The crosstalk 
between tumor cells and the surrounding microenvironment plays a pivotal role in 
modulating glioma growth and aggressiveness. Resident microglia, with central 
nervous system (CNS)-tailored functions, and infiltrating tumor-associated 
monocytes/macrophages (iTAMs) from the bone marrow, comprise the most abundant 
non-neoplastic cells in this microenvironment. Recently, we have identified the human 
microglia molecular signature in homeostatic conditions. Here, we propose to 
determine the global changes microglia underwent during glioma progression, 
correlating them to the oncogenic molecular alterations in the tumor, particularly GBM. 
Fresh microglia were isolated from human lower grade gliomas (astrocytoma and 
oligodendroglioma, LGG) and GBMs and RNA sequenced. Our data suggests not only an 
immune-suppressive profile for tumor microglia, but also alterations largely related to 
a highly proliferative and mobile phenotype for microglia, that increases with disease 
progression. In agreement with this, we observed overexpression of genes coding for 
extracellular matrix proteins, which were shown to correlate to the mesenchymal GBM 
subtype. Further exploring the characteristics and dynamics of microglia within 
different grades and subtypes of glioma is crucial for a better understanding of the role 








Gliomas are a heterogeneous group of primary neuroectodermal tumors, 
originating from glial cells – such as astrocytes and oligodendrocytes, or their 
progenitors. The current classification of the World Health Organization (WHO) 
associates clinical and histological information with mutational data, classifying diffuse 
astrocytomas, oligodendrogliomas and glioblastomas (Louis et al., 2016; Parsons et al., 
2008). Glioblastomas are extremely aggressive, highly malignant, and the most frequent 
of gliomas. Their main features include high mitotic and vascular proliferation rates, 
necrosis and resistance to both chemotherapy and radiotherapy treatments (Cloughesy 
et al., 2014). Advances in integrated large scale strategies, as exome and transcriptome 
approaches, allowed the identification of genetic alterations singular to GBM’s genesis 
and progression (Brennan et al., 2013a; Phillips et al., 2006; Stieber et al., 2014; 
Verhaak et al., 2010). These genetic studies have identified four molecular subtypes of 
GBM: proneural, classical, neural and mesenchymal; this last subtype has the worst 
prognosis. 
Glioma tumorigenicity is not exclusively the result of its genetic alterations. 
The crosstalk between tumor cells and their surrounding microenvironment plays a 
crucial role in modulating glioma growth and aggressiveness. This microenvironment 
includes cancer stem cells, endothelial cells, pericytes and normal CNS cells, such as 
glial cells, neurons and microglia (Charles et al., 2011). The most abundant, non-
neoplastic cells in this microenvironment belong to the myeloid lineage, comprising of 
resident microglia, and infiltrating tumor-associated monocytes/macrophages (further 
called iTAMs) originating in the bone marrow (Hambardzumyan et al., 2015). There are 
conflicting studies regarding the role of such cells in tumor progression. While some 
claim better outcomes for patients with high levels of immune cells, either infiltrates or 
CNS resident cells, many others have assessed the same phenomena and related it to 
poorer prognosis (reviewed by Fridman et al (Fridman et al., 2012)). Such divergence 
in results seems to originate from the different functional and activation states innate 
immune cells can adopt within a tumor and at different time points. Historically, 
microglia and iTAM activation has been classified as classic (M1) and alternative (M2) 
(Galdiero et al., 2013; Hao et al., 2012; Mantovani et al., 2002). However, considering 
their ability to respond readily to stimuli, changes the microenvironment can lead both 
to anti or pro-tumoral responses.  
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In this study, we aim to characterize the gene expression profile of microglia 
isolated from human gliomas (glioblastoma and lower grade gliomas) and to compare it 
to a normal microglia set from post-mortem cortical tissue. We observed that changes in 
microglial cells exceed the M1/M2 polarization, and display gene expression alterations 
in signaling pathways of proliferation, migration and invasiveness. We also analyzed 
the expression of the selected targets in the tumor-microglia transcriptome in a RNA-
Seq database of TCGA cohort of GBM cases with molecular stratification, and 
demonstrated that these overexpressed tumor-microglia targets associated to the most 
invasive mesenchymal subtype with the worst prognosis. Taken together, our data 
provides a set of targets involved in the crosstalk between the tumor cell and 










Human Brain Tissue and Ethical Statement 
 
Six glioma samples were obtained during therapeutic surgery of patients 
treated by the Neurosurgery Group of the Department of Neurology at Hospital das 
Clínicas at the School of Medicine of the University of São Paulo, in the period of 2000 to 
2015. Diagnosis were confirmed by neuropathologists from the Division of Pathological 
Anatomy of the same institution, according to the WHO grading system. Patient 
information and clinical findings are presented in Supplemental Table 1. Samples were 
macrodissected and immediately snap-frozen in liquid nitrogen upon surgical removal. 
A 4µm-thick cryosection of each sample was analyzed under a light microscope after 
hematoxylin-eosin staining for assessment of necrotic, cellular debris and non-
neoplastic areas, followed by removal from the frozen block by macrodissection prior 
to RNA extractions. Written informed consent was obtained from all patients according 
to the ethical guidelines approved by the Department of Neurology, School of Medicine, 
University of São Paulo (0599/10). 
Human brain tissue was collected from the right parietal cortex during the 
course of full body autopsy. This cohort is part of our previous study The human 
microglia transcriptome and age-associated changes in actin dynamics and cell function 
(Galatro et al, submitted. Refer to Chapter 6).  
 
Microglia isolation from glioma surgical resected tissue and post mortem 
parietal cortex  
 
Pure human microglia population was isolated from glioma surgical resection 
(n=6, of which: 3 GBMs, 1 AGII, 1 AGIII and 1 ODII; herein called lower-grades gliomas, 
LGG), according to our recently published protocol (Galatro et al., 2017). Briefly, 
samples were collected either during the course of brain surgery or full body autopsy 
(right parietal cortex) and collected in ice-cold HBBS (Lonza, Switzerland) 
supplemented with 15 mM HEPES (Lonza) and 0.6% glucose (Sigma-Aldrich, USA). The 
brain tissue was dissociated in a glass tissue homogenizer and filtered using a 300 μm 
sieve, followed by a 106 μm sieve to obtain a single cell suspension. Cells were pelleted 
by centrifugation at 220 rcf for 10 min. (acc: 9, brake: 9, 4°C). The pellet was 
resuspended in 22% Percoll (GE Healthcare, UK), 40 mM NaCl and 77% myelin gradient 
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buffer (5.6 mM NaH2PO4·H2O, 20 mM Na2HPO4·2H2O, 140 mM NaCl, 5.4 mM KCl, 11 mM 
Glucose, pH 7.4). A layer of PBS was added on top, and this gradient was centrifuged at 
950 rcf for 20 min. (acc: 4, brake: 0, 4°C). The myelin layer and the remaining 
supernatant were carefully removed and the pellet resuspended in a solution of 60% 
Percoll, which was overlaid with 30% Percoll and PBS respectively, and centrifuged at 
800 rcf for 25 min (acc: 4, brake: 0, 4°C). The cell layer at the 60-30% Percoll interface 
was collected with a pre-wetted Pasteur pipette, washed and centrifuged at 600 rcf for 
10 min (acc:9, brake: 9, 4°C). The final pellet was resuspended in HBBS without phenol 
red (Lonza) supplemented with 15 mM HEPES (Lonza) and 0.6% glucose (Sigma-
Aldrich). Fc receptors were blocked with human Fc receptor binding inhibitor 
(eBioscience, Affymetrix, USA) for 10 min on ice. For sorting, cells were incubated for 
20 min on ice with anti-human CD11b-PE (Biolegend, USA) and anti-human CD45-FITC 
(Biolegend) and subsequently washed with HBBS without phenol red. The cells were 
passed through a 35-μm nylon mesh and collected in round bottom tubes (Corning, 
USA) and sorted using a BD Biosciences FACSAria II cell sorter. Cells were sorted based 
on CD11bhigh/CD45int expression and negative staining for DAPI and collected in 
RNAlater (Qiagen). Cells with the profile of myeloid infiltrates were collected 
separately. Sorted cells were centrifuged 5,000 rcf for 10 min and pellets were lysed in 
RLT-Plus buffer (Qiagen) for RNA extraction. 
 
 
RNA extraction and RNA sequencing (RNA-seq) 
 
Total RNA was extracted from flow cytometry–sorted cells using an RNeasy 
and AllPrep Micro Kit (Qiagen, Germany), according to the manufacturer's protocol. 
RNA quality was checked with RNA Screen Tape (Agilent technologies, USA). RNA-Seq 
were performed at the next generation sequencing facility core (SELA – 
Sequenciamento em Larga Escala) at the University of São Paulo. SMARTer Stranded 
Total RNA-Seq Kit - Pico Input (Takara Bio, JP) cDNA libraries were prepared starting 
from 500 pg of total RNA. RNAs were fragmented by heat in the presence of divalent 
cations. The transcript for the first strand cDNA was prepared with reverse 
transcriptase and random primers. The second strand cDNA was synthetized by 
reverse transcriptase. Adaptors and index of unique sequence were added to cDNA 
fragments by PCR. rRNA fragments were captured and degraded with RiboGone probes 
and enzyme and the remaining library fragments were enriched by PCR. Final libraries 
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were quantified by qPCR (Kappa Library Quantification Kit, Illumina, Kappa 
Biosystems, USA), and the median size of the libraries determined by TapeStation 2200 
(Agilent Technologies, USA), using the High Sensitivity D1000 ScreenTape assay. 
Sequencing was performed as a 2x126 paired-end, dual index run, on a HiSeq 2500 
(illumina, USA) with V4 reagents. 
 
RNA-Seq data analysis  
 
RNA-Seq data analysis of six tumor microglia samples was done using the 
hereinafter described pipeline, developed in the SELA facility. Metrics for FASTQ files 
were done using the FastQC program. All samples presented sufficient quality, with 
>95% of reads presenting quality above Q30. Despite sufficient quality with .FASTQ 
files, we decided to remove possible traces of adapter sequences. We also removed low 
quality bases from extremities and excessive short reads. These procedures were 
executed using the software bbduk (BBMap - Bushnell B. – 
www.ourceforge.net/projects/bbmap/). FASTQ files post-processing were aligned to 
hg38 version of human genome, acquired from the website www.ensembl.org. Reads 
were aligned to the reference-genome using the STAR aligner (Dobin et al., 2013) 
software. The resulting .BAM files (reads aligned to genomic coordinates) were 
submitted to metric analysis through RNA-SEQC software(DeLuca et al., 2012). 
All the following steps were done using R program, with the exception of the 
generation of the raw counts spreadsheet. The .BAM files, aligned to the genomic 
coordinates, were quantified by the RSEM software (Li and Dewey, 2011). 
Quantification was done considering gene’s full extension. Genes that were not 
expressed in at least 20% of samples were removed from the matrix. After this step, 
22070 genes were considered as expressed. 
Data normalization was done using the limma-voom pipeline, obtained 
through the R-Bioconductor package (Ritchie et al., 2015).  Annotation of each gene was 
done using the biomaRt (R-Bioconductor) software. Class comparison consisted of: 
tumor microglia versus autopsy microglia. The Benjamini-Hochberg procedure was 
used for false-positive controls. Using this pipeline, we identified 10462 differentially 
expressed genes.  
For gene set enrichment and pathway analysis, we used the ROAST (Wu et al., 
2010) tool from the limma package. Unsupervised analysis consisted of the 
Independent Component Analysis (ICA) and the co-regulatory network analysis 
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CoRegNet (Nicolle et al., 2015). ICA was used to determine the differentially expressed 
genes according to the molecular signature found in samples. CoRegNet analysis 
provided a set of genes representing the active transcriptional programs in our 







Isolation of pure microglia population from human glioma samples 
 
Human glioma samples were collected during the course brain surgery, 
followed by tissue processing and acute isolation of viable microglia by FACS sorting. 
The sorting strategy followed was previously described (Galatro et al., 2017), with 
particular care to avoid contamination of the microglia population with other myeloid 
infiltrates. Figure 1A depicts the isolation workflow and in Figure 1B the expressions of 
known microglia genes versus genes specific for other CNS cells are depicted, in order to 
assess purity. For one GBM sample, it was possible to collect samples in the myeloid 
infiltrates gates (further referred to as iTAM). RNAs were extracted and their quality 
analyzed. In total, 6 samples of microglia were obtained from glioma surgery (3 GBMs 
and 3 LGG) and one of iTAMs. Paired-end Illumina high quality deep sequencing was 
performed and the generated data was analyzed conjointly with n=10 samples of 
microglia isolated from autopsy cortical brain tissue. These samples are part of our 
work, The human microglia transcriptome and age-associated changes in actin dynamics 
and cell function (Galatro et al, submitted. Refer to Chapter 6). RNA-Seq data was pre-





Figure 1: Isolation workflow and purity analysis of human glioma microglia. A) 
Illustration depicting the workflow from the collection of brain tumor tissue during the 
course of surgery, to the isolation and RNA-Seq of human glioma microglia. B) RNA-
sequencing of ex-vivo isolated tumor microglia and iTAMs revealed very low 
expression of known genes in neurons, astrocytes and oligodendrocytes in comparison 
to RNA-Seq from cortical brain tissue (from The human microglia transcriptome and 
age-associated changes in actin dynamics and cell function (Galatro et al, submitted. 
Refer to Chapter 6). Differences in tumor microglia and iTAMs also indicate the 
differences between these populations. These data demonstrate that a highly pure 
microglia population was sorted from our cohort of human glioma samples. 
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Genes differentially expressed between tumor and normal microglia 
 
Gene expression analysis revealed major differences between tumor and 
normal cortical microglia. Principal component analysis (PCA) plots (Figure 2A) 
showed that iTAMs differed from both normal and tumor microglia samples; also, 
normal microglia segregated from tumor microglia. Tumor microglia samples did not 
segregate according to tumor subtype, possibly reflecting the intrinsic heterogeneity in 
those samples. The pathways associated with genes expressed in tumor (GBM and LGG) 
microglia were determined with GSEA enrichment analysis. GBM microglia gene 
expression profile (Figure 2B) was enriched for general processes, such as proliferation 
related pathways (“cell proliferation” and “cytoskeleton organization and biogenesis”); 
and motility related pathways (“extracellular matrix”, “cell migration” and “locomotory 
behavior”), but also for CNS specific pathways, like “synaptic transmission”, “brain 
development” and “CNS development”. The oncogenic-related pathways were 
represented by “angiogenesis”, “epithelial to mesenchymal transition”, “hypoxia” and 
“myc targets”. In LGG microglia, inflammatory-specific pathway “TNF signaling via 
NFKB”, “chromatin remodeling process” and transcription related “transcription factor 
binding” and “regulation of transcription DNA dependent” (Figure 2C) were 
significantly enriched. The most notable pathways when we compared the profile of 
GBM and LGG microglia were “response to hypoxia”, “extracellular matrix”, “basement 
membrane” and “positive regulation of response to stimulus” (Figure 2C). These results 








GBM and LGG microglia signature 
 
We next established a representative gene set for both GBM and LGG microglia. 
The differentially expressed genes between both tumors types and normal microglia 
were filtered with the following criteria: logFC > 3 (for upregulated genes), logFC < -3 
(for downregulated genes) and p < 0.001. With these stringent criteria, the GBM 
microglia signature consisted of 332 genes, while the LGG microglia signature consisted 
of 90 genes (Figure 3). 213 genes were upregulated in GBM microglia in comparison to 
LGG microglia. In our previous work, we determined a core signature for human 
microglia gene expression from cortical autopsy samples using stringent variables. We 
compared the overlap between the core signatures of normal, GBM and LGG microglia 
and, surprisingly, detected no overlap.  
Figure 2: PCA analysis and biological pathways in glioma microglia. A) Principal 
component analysis of RNA-Seq showed that normal microglia were highly similar 
while tumor microglia segregated differentially and furtherly. iTAMs were the most 
different sample. GO analysis for GBM (B), LGG (C) and the comparison between GBM 
versus LGG (D) microglia showed biological pathways related to proliferation, 




Most genes in the LGG microglia core were also present in GBM microglia 
signature, even at higher levels. We highlight FCMR, IER2, and the AP-1 transcription 
factor complex members FOS and JUND as genes exclusive for the LGG microglia 
signature. GBM microglia core genes comprised inflammation-related gene families, 
such as chemokines (CCL3, CCL4, CCL8, CXCL2, CXCL3, CXCL8, CXCL9, CCR7), interleukins 
(IL15, IL2RA, IL7R), antigens (CD72, CD109 and CD209), and anti-inflammatory markers 
(CD163 and ANXA1). Receptors of growth factors, like EGFR and PDGFRa, 
developmental genes, like NES and POU3F2/3, extracellular matrix (ECM) genes - FN1, 
TNC, THBS, BCAN, and members of the SRY (sex determining region Y) family of genes – 
SOX1, SOX2, SOX11, SOX21 were also present in GBM microglia core. 
We were also able to collect one sample of iTAMs from a GBM case. Despite 
being statistically underpowered, iTAMs was more similar to GBM/LGG microglia than 
control microglia. However, major differences between iTAMs and GBM microglia 
signature were also identified as differentially expressed surface receptors like ROBO1 
and PDGFRA in GBM microglia, MARCO and MET in iTAMs. 
We next aimed to evaluate the expressions of the human normal microglia core 
genes in tumor microglia. Figure 4 depicts the expressions 30 genes from the core of 
normal human microglia in the tumor microglia cohort. The majority of the analyzed 
Figure 3: Core genes in glioma microglia. Differentially expressed genes from the 
comparison between both tumors types to normal microglia were filtered with the 
following criteria: logFC > 3 (for upregulation), logFC < -3 (for downregulation) and p < 
0.001 for both cases. The GBM microglia signature contained 332 genes, the LGG 
microglia signature consisted of 90 genes 
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genes was differentially expressed between the LGG and GBM microglia demonstrating 
changes in the expression profile of the microglia in the tumor environment. 
 
 
Independent Component Analysis and pathways in tumor microglia 
 
In order to determine the set of genes presenting significant expression 
alterations between the two groups, normal and tumor microglia, studied, we applied 
Independent Component Analysis (ICA) to the RNA-Seq data distributed in 6 
components.  We then selected the best component that segregated normal from tumor 
microglia, and the LGG from GBM microglia. Components 1 showed the best separation 
between normal and tumor microglia, and component 6 for LGG and GBM microglia. 
(Figure 5).   
Figure 4: Expression of human normal microglia core genes in glioma microglia. Genes 
from the normal microglia core presented differentially expressed in tumor microglia, 
and also when compared LGG to GBM microglia, demonstrating significant changes of 




































In component 1, the upregulated genes in tumor microglia relative to normal 
microglia included: chemokines CXCL2/8, CCL3/4/5 and receptor CCR7; genes related to 
mitotic stimuli responses ASPM and EGR1-4; to development SOX2/10 and KLF2/4/10; 
metalloproteinase MMP19 (Figure 6).  GSEA analysis of the set of upregulated genes in 
the component 1 revealed signaling pathways related to proliferation (“regulation of 
cell proliferation”, “regulation of cell cycle), and to motility (“regulation of granulocyte 
chemotaxis”, “positive regulation of leukocyte chemotaxis”). Additionally, were also 
observed pathways associated to “response to hormone” and “regulation of apoptotic 
process”. Downregulated genes in this component 1 included LTB, PPP1RC3 and CA13. 
Figure 5: Hierarchically clustered Z-score expression heatmap of the differentially 








Component 6 of the ICA analysis separated GBM from LGG microglia. The 
analysis of this component has also shown a very similar expression profile between 
iTAMs and GBM microglia. The downregulated genes in GBM microglia compared to 
LGG microglia in this component 6 fitted to any particular pathway, however, we 
highlighted the significant differential expression of HIST2H2AA3, CXCL12, P2RY14, 
TAL1 and FOXP2 between these two groups, LGG and GBM microglia. On the other hand, 
the upregulated genes associated to pathways related to proliferation (such as 
“regulation of transcription involved in G1/S transition of mitotic cell cycle”, “mitotic 
spindle assembly” and “microtubule cytoskeleton organization involved in mitosis”), 
and, also related to extracellular matrix organization and leukocyte migration. Among 
those upregulated genes in GBM microglia compared to LGG microglia NES, MELK 
(development), FOXM1 (cell cycle), CXCL3 (chemoattractant chemokines), IL2RA, IL7R 
(interleukin receptors), FN1, THBS1, TNC and VCAN (ECM), ITGA4 (integrin) presented 
interesting increment of their expression in parallel to the progression of malignancy 













Figure 6: Upregulated genes in tumor microglia in the Component 1 which segregated 
normal from glioma microglia are presented, including chemokines CXCL2/8 and 
CCL3/4/5; mitotic stimuli responses related genes ASPM, EGR1-4 and CDK1; 
development related genes SOX2/10 and KLF2/4/10; metalloproteinase MMP19; and 
LMNA. Despite separating tumor from normal microglia, no significant difference of 




Figure 7: Upregulated genes of Component 6 associated to pathways related to 
proliferation, extracellular matrix organization and leukocyte migration.  NES, MELK 
(development related genes), FOXM1(cell cycle control), CXCL3 (chemoattractant 
chemokine), IL2RA (interleukin receptors), FN1, THBS1, TNC, VCAN (ECM) and ITGA4 




Figure 8 shows the functional protein association network resulting from 
upregulated genes in the Component 6 analysis, when compared LGG to GBM microglia 
transcriptome. 
    
Transcription network in tumor microglia  
 
CoRegNet analysis provided a set of genes representing the co-operative 
regulators and the active transcriptional programs in our analyzed cohort. Figure 9 
displays the results from this analysis. It is interesting to notice that TAL1, ID1 and ID3, 
three coding genes for bHLH proteins, MEIS1 and ZNF556 presented low regulation 
activity in tumor-microglia compared to normal microglia. Active transcription factors 
add up to 43, including the previously mentioned EGR1-3 and KLF2/4/6/10, histone 
Figure 8: A predicted protein-protein interaction network of the upregulated genes of 
Components 6 analysis, comparing LGG to GBM microglia expression profile. 
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acetylating CREBBP, along with FOS family (FOS, FOSB, FOSL1, FOSL2), VDR, RUNX3, 
BCL6, NFKBIA, MAFF and MITF. The heat map on Figure 9 displays how these 




























Figure 9: CoRegNet analysis. Using BioConductor package CoRegNet, transcriptional 
regulators of human glioma microglia were identified. A) A heat map displaying the 
expression of these transcription factors in our cohort. B) The predicted glioma 
microglia transcriptional network. In red the active transcription regulators, and in 





A set of differentially expressed genes were detected within GBM microglia 
samples. This led us to question whether these were related to the previously described 
GBM subtypes (Brennan et al., 2013b; Cloughesy et al., 2014; Phillips et al., 2006; 
Verhaak et al., 2010). The genetic alterations within these tumors might influence the 
surrounding microenvironment and influence the microglia transcriptome. We 
previously assessed the genetic alterations of the corresponding bulk tumors of our 
GBM microglia cases (refer to Chapter 3). In the present tumor-microglia series, two 
samples were classified as classical GBM and one as mesenchymal. Our cohort is 
underpowered to make any inference if GBM subtypes somehow impact on microglia 
and iTAMs gene expression. Hence, we proceeded to investigate how this set of genes 
was expressed in a TCGA cohort of GBM samples stratified by molecular alteration. 
A TCGA-GBM analyzed cohort contained samples from whole-tissue RNA-Seq. 
Our inquiry was to which GBM subtype (mesenchymal, classical, neural or proneural) 
was enriched for microglia. For that, we evaluated a gene set of membrane associated 
proteins from the normal microglia core signature previously mentioned (refer to 
Chapter 6). Members of the FC-gamma receptor family, integrins and purinergic 
receptors were selected (Figure 10). We observed a clear upregulation of these 
markers in the mesenchymal subtype of GBM. This observation agrees with current 
data reporting mesenchymal GBM enriched for myeloid activation/inflammation 
markers (Engler et al., 2012; Rutledge et al., 2013; de Vrij et al., 2015; Zanotto-Filho et 
al., 2016). Interestingly, the most notable genes with lower expression in the 




Figure 10: Normal microglia core genes are upregulated in the Mesenchymal GBM 
subtype. Members of the FC-gamma receptor family, integrins, complement and 
purinergic receptors were selected for this analysis. Noteworthy exceptions include 
P2RY12 and CX3CR1. MES, mesenchymal; CLA, classical; NEU, neural, PRO, proneural 
(+) IDH1 mutated and (-) IDH1 wild-type. 
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Genes that were upregulated in tumor-microglia from the above analysis did 
not present any specific pattern and their expressions varied among GBM subtypes 
(Supplemental Figure 1). However, we noticed that genes encoding ECM proteins from 
Component 6 analysis, with the exception of VCAN, were significantly higher expressed 
in the mesenchymal GBM subtype (Figure 11). This data indicates that the increased 
expression of these genes in GBM might be related to a microglial source.  
 
  
Figure 11: ECM proteins coding genes are upregulated in the Mesenchymal GBM 
subtype. Despite not present any specific pattern and their hyper-expression varying 
among GBM subtypes, we observed higher levels of ECM proteins coding genes from 
component 6 in mesenchymal GBMs. MES, mesenchymal; CLA, classical; NEU, neural, 





In this study, we report differential gene expression profile between glioma-
derived and normal microglia, as well as the differences found between microglia 
derived from lower grade gliomas and from glioblastomas. Most studies regarding 
human microglia lack an appropriate control population for comparison, relying on 
samples from epilepsy surgeries, which display inflammatory alterations intrinsic to 
the disease (Devinsky et al., 2013; Eyo et al., 2016). Our control population consists of 
microglia isolated from cortical post-mortem tissue, whose transcriptome has been 
extensively analyzed (refer to Chapter 6). Our tumor microglia analysis was based on 
the comparison to a set of normal microglia samples from this study, allowing for a 
comparison between tumor and normal microglia, and between LGG and GBM 
microglia. 
Isolation of pure human microglia in the presence of myeloid infiltrates is 
difficult. Several protocols have been published, by our group and others (Olah et al., 
2012; Rustenhoven et al., 2016), aiming to diminish contamination with other 
leucocytes or brain cells. Our latest protocol (Galatro et al., 2017) (refer to Chapter 5) 
focuses on high purity population (above 98% of microglial purity) and employs a 
sorting strategy that clearly separates microglia cells from myeloid infiltrates. Further 
transcriptome analysis corroborates this claim, as markers for neurons, astrocytes, 
oligodendrocytes and immune infiltrate were low or not present at all in our data 
(Figure 1). 
 
Human tumor microglia display changes that go beyond an inflammatory 
phenotype 
 
Comparison of tumor versus normal microglia indicated that tumor microglia 
samples are not as homogenous as normal microglia. Heterogeneity in gliomas, under 
histological and molecular parameters, is a known fact (reviewed by (Filbin and Suvà, 
2016)). If and how these intrinsic differences affect the microenvironment and as a 
consequence influence microglia gene expression is unclear. It is clear, however, that 
both tumor grade (LGG and GBM) and molecular subtype (in the case of GBM subtypes) 
have major influences on the myeloid cells in the microenvironment. 
While assessing which biological pathways were associated with the 
differentially expressed genes in tumor versus normal microglia, we observed that, 
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while inflammation related pathways were altered, the most prominent changes were 
related to other pathways. Proliferation, cell cycle control and motility (the last one 
includes extracellular matrix-related changes) were most affected in tumor-microglia. 
It also seems that, even if markers previously identified in non-neoplastic microglia are 
still expressed, tumor-microglia undergo such drastic changes upon glioma stimuli, that 
a different set of markers were hyperexpressed in tumor-microglia.  
Despite the high levels of anti-inflammatory markers, such as CD163, CD209 
and ANXA1, the set of chemokines and other secreted factors differentially expressed 
that characterize a polarized M1 or M2 phenotype was difficult to recognize in tumor 
microglia. A recent report where the transcriptome of a mixed population of microglia 
and iTAMs from human GBMs was analyzed (Szulzewsky et al., 2016) also showed a 
lack of an inflammatory profile for those cells. In that study, one possible explanation 
raised was the fact that normal and tumor samples were not age-matched, as is the case 
with our study. An intrinsic inflammation in normal (older) microglia samples would be 
the cause for such result. As we demonstrated in Chapter 6, aging in human microglia 
does not present an inflammatory profile, but is related to changes in actin dynamics. In 
our tumor microglia analysis, we observed a plethora of genes, involved in unexpected 
biological pathways, discussed below.  
 
Transcriptome signature for glioma microglia 
 
With stringent criteria, we could determine core genes for both GBM and LGG 
microglia, and through ICA analysis, we were able to further identify differentially 
expressed genes and to associate them to specific biological functions. Interestingly, we 
identified a set of genes by both analysis: class comparison and independent 
component analyses. A considerable number of genes selected as differentially 
expressed in LGG microglia compared to normal microglia were also present in GBM 
microglia, although at higher levels, suggesting the participation of these genes in the 
malignant progression of the tumor. This finding corroborate a previous observation 







EGR1-4 genes were differentially expressed in both LGG and GBM microglia 
and the lower expression in normal microglia suggest that they might also be important 
for the shift from normal to tumor microglia. EGRs are zinc finger-containing 
transcription factors first discovered in the search for genes whose expression was 
induced by growth factors; they have been associated to both lymphoid and myeloid 
hematopoiesis (Gashler and Sukhatme, 1995; Gómez-Martín et al., 2010). Further 
studies postulated EGR1 as central for the regulation of mitotic processes, ensuring that 
weak signals did not trigger cell proliferation (Zwang et al., 2011). EGR1 also mediates 
responses to ischemia in mononuclear phagocytes (Bosco et al., 2008), has been 
recently associated with tumor-specific education of microglial cells in mice (Bowman 
et al., 2016), and induces the expression of IL6, promoting protective effects in the CNS 
upon stimuli with anti-inflammatory molecules (Casella et al., 2016) . Along with EGR1, 
EGR2 promotes differentiation of monocytes into macrophage (Laslo et al., 2006) and is 
essential for CSFR1 expression in the course of macrophage differentiation from 
myeloid progenitors by forming an active enhancer complex with PU.1 and 
RUNX1(Krysinska et al., 2007). Their roles myeloid specific and in proliferation/cell 
cycle control as tracked by ICA components 1 and 6 analyses highlight EGRs as 
regulators for the microglia response to glioma stimuli. 
Krüppel-like transcription factors (KLFs) have been previously associated with 
monocyte/macrophage differentiation or activation (Cao et al., 2010). KLF4, a major 
downstream target of IRF8 and PU.1, is critical for development of the monocyte 
lineage (Terry and Miller, 2014), but not for microglia development (Kierdorf et al., 
2013). In addition, KLF4 has been associated with IL1β expression and the regulation of 
neuro-inflammation and immunomodulatory activities in murine microglia cell line 
(Kaushik et al., 2010, 2013). KLF6 has been associated to macrophage polarization 
towards a pro-inflammatory phenotype (Bi et al., 2016; Date et al., 2014), while KLF2 
and KLF10 were proposed as promoters of a supportive and anti-inflammatory 
phenotype (Das et al., 2012; Mahabeleshwar et al., 2011; Papadakis et al., 2015). In our 
evaluation, KLF2/6 levels were upregulated in LGG microglia, and their expression 
levels were also high in GBM microglia. Interestingly, KLF4/10 expression levels 
increased with tumor grade. 
Activator-protein 1 (AP-1 complex), encoded by genes from both the FOS and 
JUN families, is also related to the activation of pro-inflammatory responses (Waetzig et 
al., 2005). In our cohort, their members showed a similar pattern to KLFs. 
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Although a specific inflammatory phenotype was lacking in the tumor-
microglia expression profile in the present study, a disbalance in the regulatory 
network of the inflammatory response of microglia along glioma progression was 
detected. A single cell approach may clarify the major players of the tumor-microglia 
during the progression from LGG to GBM. 
Among the lower active transcription factors in tumor-microglia, we 
highlighted genes coding for basic helix-loop-helix proteins (bHLH), TAL1 and ID1/3. 
TAL1 is one of the transcriptional regulators in adult microglia, possibly forming a 
complex with RUNX1 and LYL1 (Wilson et al., 2009, 2010), and activating the 
transcription of many microglia specific genes. The loss of the “normal” microglia 
identity in gliomas might be explained by the downregulation of a factor such as TAL1. 
ID proteins are dominant negative transcription factors, a highly evolutionarily 
conserved group of proteins that play crucial roles in cellular process ranging from cell 
cycle control, differentiation and tumorigenesis (Benezra et al., 1990; Lasorella et al., 
2014). We have recently characterized ID proteins expression in human glioma whole 
tissue (refer to Chapter 3), assessing their differential expression according to tissue of 
origin (astro or oligocytic) and GBM subtype. It now becomes clear that the differences 
found in IDs expression in our previous work are not related to the inflammatory 
microenvironment in gliomas, and are mostly related to tumor cells. 
 
Extracellular matrix modulation and invasiveness 
 
Our analysis revealed that tumor-microglia express high levels of genes related 
to extracellular matrix remodeling, such as fibronectin (FN1), tenascin-C (TNC) and 
thrombospondin-1 (THBS1), along with invasiveness related ANXA2. FN1 is known to 
be highly expressed in GBM, in comparison to non-invasive pilocytic astrocytoma (AGI). 
Functional studies in GBM cell lines have correlated this overexpression to increased 
tumor cell proliferation, invasion, resistance to ionizing irradiation and enhanced in 
vivo angiogenic potential (Blandin et al., 2016; Colin et al., 2006; Serres et al., 2014). 
Tenascin-C has been shown to limit the pro-inflammatory response, as well as to 
increase the invasive phenotype of iTAMs and to control the “go or grow” switch in 
glioma in vivo (Brellier and Chiquet-Ehrismann, 2011; Van Obberghen-Schilling et al., 
2011; Xia et al., 2016). The role of THBS1 in gliomas is unclear, as it has been associated 
to tumor suppression given its anti-angiogenic properties(Kazerounian et al., 2008), 
but also to increased invasiveness at the border of gliomas (Gritsenko et al., 2012). 
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Recent studies have demonstrated that ANXA2, a calcium-binding cytoskeletal protein 
expressed on the surface of several cell types, stands out as an epigenetically controlled 
master regulator of mesenchymal transformation in glioma (Kling et al., 2016), 
associated with patient survival. Also, it has been shown that GBM cell migration and 
invasion are sustained by ANXA2 (Maule et al., 2016). While these previous studies 
focused on tumor cells, we detected microglia as a major source for these proteins.  
Among GBM subtypes, the above mentioned targets related to ECM modulation 
were highest in mesenchymal subtype, presenting the highest invasive rate and the 
worst prognosis (Balbous et al., 2014; Carro et al., 2010).  
The present findings shed new light on the changes human microglia undergo 
upon glioma stimuli and open questions about the regulatory processes between tumor 
and microglia compartments. Addressing these questions in additional studies may lead 
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